NCT02921256 2025-12-04
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
41 trialsNCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01814501 2025-02-05
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00807911 2024-10-23
Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
Asan Medical Center
Phase 2 Completed
NCT03300544 2024-05-23
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02017704 2023-10-17
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00303628 2023-07-06
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Terminated
NCT00098787 2023-07-05
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00308516 2021-12-10
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02319304 2021-11-04
GCC 1314
University of Maryland, Baltimore
Phase 2 Terminated
NCT02340949 2021-05-03
RIA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT01280643 2021-03-15
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Fox Chase Cancer Center
Phase NA Terminated
NCT02641691 2021-02-18
NORMAL-R
Washington University School of Medicine
Phase 2 Completed
NCT01481545 2021-02-03
BRANCH
National Cancer Institute, Naples
Phase 2 Completed
NCT01363843 2020-06-11
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Brown University
Phase 2 Completed
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00081289 2020-02-27
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00580073 2019-12-13
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
University of Wisconsin, Madison
Phase 2 Terminated
NCT00321685 2019-03-27
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00611858 2019-01-08
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00068692 2018-12-04
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02305758 2018-11-20
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00613080 2018-09-25
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00832299 2018-03-01
Neo-Adjuvant FOLFOX for Rectal Carcinoma
Beth Israel Medical Center
Phase 2 Terminated
NCT01279681 2017-12-08
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00682786 2017-10-06
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Washington University School of Medicine
Phase 2 Completed
NCT00865189 2017-08-04
INOVA
Hoffmann-La Roche
Phase 2 Completed
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00307736 2017-05-10
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT00002842 2017-04-11
Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01060007 2017-03-08
Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Washington University School of Medicine
Phase 2 Completed
NCT01749956 2017-02-07
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00527111 2016-11-03
Pre-op Rectal ChemoRad +/- Cetuximab
US Oncology Research
Phase 2 Completed
NCT01320683 2016-07-19
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT00462501 2016-01-20
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00100841 2015-07-27
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00499369 2014-07-31
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01198548 2014-07-21
High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00942266 2014-06-23
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
Roswell Park Cancer Institute
Phase 2 Completed